96 research outputs found
Optimisation des Pertes par Commutation dans un Convertisseur Modulaire Multiniveaux (MMC)
International audienceLes pertes dans une liaison à courant continu à haute tension sont un facteur pénalisant (4000 €/kW sur une duréede 30 ans). L’inconvénient vient des structures de type Onduleurde tension qui ont des pertes élevées (1.8%) relativement auxstructures à base de thyristors. L’arrivée des convertisseurs detype Modulaires Multiniveaux (MMC) a permis de réduire cespertes à 1%. Cet avantage permet d’envisager une forte utilisationde cette structure dans des applications HVDC. Le but de cetravail est d’étudier le contrôle bas niveau de ce convertisseur quicorrespond au choix des sous-modules à utiliser et à l’équilibragedes condensateurs afin de minimiser la fréquence de commutation.En se focalisant sur un contrôle de type ondulation des tensions dessous modules, une amélioration a été apportée via une réductionde la fréquence de commutation moyenne de ces sous-modules. Dessimulations sous MATLAB/Simulink ont été conduites et ontpermis de valider la méthode proposée
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer
Contains fulltext :
202562.pdf (Publisher’s version ) (Open Access
What defines a great surgeon? A survey study confronting perspectives
BackgroundThe definition of a great surgeon is usually reported by surgeons themselves. The objective of the study was to define a multifaceted definition of a great surgeon, by confronting patients', healthcare workers', and surgeons' perspectives.Study designAn online open-ended questionnaire was created to identify three qualities and three shortcomings defining a great surgeon. Age, gender, and profession of respondents were collected. Responses with a similar meaning were combined into word groups and labeled within four themes: human qualities, technical surgical skills (TSS), non-technical skills (NTS), and knowledge. Multivariate analyses were conducted between themes and respondent characteristics.ResultsFour thousand seven hundred and sixty qualities and 4,374 shortcomings were obtained from 1,620 respondents including 385 surgeons, 291 patients, 565 operating theater (OT) health professionals, and 379 non-OT health professionals. The main three qualities were dexterity (54% of respondents), meticulousness (18%), and empathy (18%). There was no significant difference between professional categories for TSS. Compared with surgeons, non-OT health professionals and patients put more emphasis on human qualities (29 vs. 39% and 42%, respectively, p < .001). OT health professionals referred more to NTS than surgeons (35 vs. 22%, p < 0.001). Knowledge was more important for surgeons (19%) than for all other professional categories (p < 0.001).ConclusionsThis survey illustrates the multifaceted definition of a great surgeon. Even if dexterity is a major quality, human qualities are of paramount importance. Knowledge seems to be underestimated by non-surgeons, although it essential to understand the disease and preparing the patient and OT team for the procedure
Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
Background Our objective was to evaluate the efficacy (clinical and biomarker)
and safety of intravenous bapineuzumab in patients with mild to moderate
Alzheimer’s disease (AD). Methods Two of four phase 3, multicenter,
randomized, double-blind, placebo-controlled, 18-month trials were conducted
globally: one in apolipoprotein E ε4 carriers and another in noncarriers.
Patients received bapineuzumab 0.5 mg/kg (both trials) or 1.0 mg/kg
(noncarrier trial) or placebo every 13 weeks. Coprimary endpoints were change
from baseline to week 78 on the 11-item Alzheimer’s Disease Assessment
Scale–Cognitive subscale and the Disability Assessment for Dementia. Results A
total of 683 and 329 patients completed the current carrier and noncarrier
trials, respectively, which were terminated prematurely owing to lack of
efficacy in the two other phase 3 trials of bapineuzumab in AD. The current
trials showed no significant difference between bapineuzumab and placebo for
the coprimary endpoints and no effect of bapineuzumab on amyloid load or
cerebrospinal fluid phosphorylated tau. (Both measures were stable over time
in the placebo group.) Amyloid-related imaging abnormalities with edema or
effusion were confirmed as the most notable adverse event. Conclusions These
phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested
doses on clinical endpoints in patients with mild to moderate AD. Some
differences in the biomarker results were seen compared with the other phase 3
bapineuzumab trials. No unexpected adverse events were observed. Trial
registration Noncarriers (3000) ClinicalTrials.gov identifier NCT00667810;
registered 24 Apr 2008. Carriers (3001) ClinicalTrials.gov identifier
NCT00676143; registered 2 May 2008
Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials
Background:
Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD).
Methods:
Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted globally: one in apolipoprotein E ε4 carriers and another in noncarriers. Patients received bapineuzumab 0.5 mg/kg (both trials) or 1.0 mg/kg (noncarrier trial) or placebo every 13 weeks. Coprimary endpoints were change from baseline to week 78 on the 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale and the Disability Assessment for Dementia.
Results:
A total of 683 and 329 patients completed the current carrier and noncarrier trials, respectively, which were terminated prematurely owing to lack of efficacy in the two other phase 3 trials of bapineuzumab in AD. The current trials showed no significant difference between bapineuzumab and placebo for the coprimary endpoints and no effect of bapineuzumab on amyloid load or cerebrospinal fluid phosphorylated tau. (Both measures were stable over time in the placebo group.) Amyloid-related imaging abnormalities with edema or effusion were confirmed as the most notable adverse event.
Conclusions:
These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical endpoints in patients with mild to moderate AD. Some differences in the biomarker results were seen compared with the other phase 3 bapineuzumab trials. No unexpected adverse events were observed
Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials
Background: Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease (AD).Methods: Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted globally: one in apolipoprotein E epsilon 4 carriers and another in noncarriers. Patients received bapineuzumab 0.5 mg/kg (both trials) or 1.0 mg/kg (noncarrier trial) or placebo every 13 weeks. Coprimary endpoints were change from baseline to week 78 on the 11-item Alzheimer's Disease Assessment Scale-Cognitive subscale and the Disability Assessment for Dementia.Results: A total of 683 and 329 patients completed the current carrier and noncarrier trials, respectively, which were terminated prematurely owing to lack of efficacy in the two other phase 3 trials of bapineuzumab in AD. The current trials showed no significant difference between bapineuzumab and placebo for the coprimary endpoints and no effect of bapineuzumab on amyloid load or cerebrospinal fluid phosphorylated tau. (Both measures were stable over time in the placebo group.) Amyloid-related imaging abnormalities with edema or effusion were confirmed as the most notable adverse event.Conclusions: These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical endpoints in patients with mild to moderate AD. Some differences in the biomarker results were seen compared with the other phase 3 bapineuzumab trials. No unexpected adverse events were observed
Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings
Abstract: Background: Recruitment is often a bottleneck in secondary prevention trials in Alzheimer disease (AD). Furthermore, screen-failure rates in these trials are typically high due to relatively low prevalence of AD pathology in individuals without dementia, especially among cognitively unimpaired. Prescreening on AD risk factors may facilitate recruitment, but the efficiency will depend on how these factors link to participation rates and AD pathology. We investigated whether common AD-related factors predict trial-ready cohort participation and amyloid status across different prescreen settings. Methods: We monitored the prescreening in four cohorts linked to the European Prevention of Alzheimer Dementia (EPAD) Registry (n = 16,877; mean ± SD age = 64 ± 8 years). These included a clinical cohort, a research in-person cohort, a research online cohort, and a population-based cohort. Individuals were asked to participate in the EPAD longitudinal cohort study (EPAD-LCS), which serves as a trial-ready cohort for secondary prevention trials. Amyloid positivity was measured in cerebrospinal fluid as part of the EPAD-LCS assessment. We calculated participation rates and numbers needed to prescreen (NNPS) per participant that was amyloid-positive. We tested if age, sex, education level, APOE status, family history for dementia, memory complaints or memory scores, previously collected in these cohorts, could predict participation and amyloid status. Results: A total of 2595 participants were contacted for participation in the EPAD-LCS. Participation rates varied by setting between 3 and 59%. The NNPS were 6.9 (clinical cohort), 7.5 (research in-person cohort), 8.4 (research online cohort), and 88.5 (population-based cohort). Participation in the EPAD-LCS (n = 413 (16%)) was associated with lower age (odds ratio (OR) age = 0.97 [0.95–0.99]), high education (OR = 1.64 [1.23–2.17]), male sex (OR = 1.56 [1.19–2.04]), and positive family history of dementia (OR = 1.66 [1.19–2.31]). Among participants in the EPAD-LCS, amyloid positivity (33%) was associated with higher age (OR = 1.06 [1.02–1.10]) and APOE ɛ4 allele carriership (OR = 2.99 [1.81–4.94]). These results were similar across prescreen settings. Conclusions: Numbers needed to prescreen varied greatly between settings. Understanding how common AD risk factors link to study participation and amyloid positivity is informative for recruitment strategy of studies on secondary prevention of AD
Bone Marrow Transplant
Mucopolysaccharidosis type I-H (MPS I-H) is a rare lysosomal storage disorder caused by α-L-Iduronidase deficiency. Early haematopoietic stem cell transplantation (HSCT) is the sole available therapeutic option to preserve neurocognitive functions. We report long-term follow-up (median 9 years, interquartile range 8-16.5) for 51 MPS I-H patients who underwent HSCT between 1986 and 2018 in France. 4 patients died from complications of HSCT and one from disease progression. Complete chimerism and normal α-L-Iduronidase activity were obtained in 84% and 71% of patients respectively. No difference of outcomes was observed between bone marrow and cord blood stem cell sources. All patients acquired independent walking and 91% and 78% acquired intelligible language or reading and writing. Intelligence Quotient evaluation (n = 23) showed that 69% had IQ ≥ 70 at last follow-up. 58% of patients had normal or remedial schooling and 62% of the 13 adults had good socio-professional insertion. Skeletal dysplasia as well as vision and hearing impairments progressed despite HSCT, with significant disability. These results provide a long-term assessment of HSCT efficacy in MPS I-H and could be useful in the evaluation of novel promising treatments such as gene therapy
- …